Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitor as potential therapeutic agent for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. Given the encouraging research outcomes, the players in the SARM1 inhibitor market have received more than USD 10 million in grants, since 2014, from the various private and public organizations.
Additionally, several patents related to SARM1 inhibitors have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 inhibitor market is anticipated to witness substantial growth in the mid to long-term.
SARM1 Inhibitor: Current Market Trend
At present, several companies worldwide have taken initiatives to develop SARM1 inhibitor for targeting multiple neurological disorders, including multiple sclerosis and amyotrophic lateral sclerosis. The market is characterized by a mix of well-established and small firms. Currently, their pipeline features both biologics and small molecules drugs, which are being evaluated in preclinical and discovery stages.
Over the years, the number of patents filed for SARM1 inhibitors has increased gradually; majority of the patents have been filed / granted in 2021. In addition, most of the patents in this domain are patent applications (96%), followed by granted patents (3%).
Future opportunities for SARM1 Inhibitors
Currently, there are no potential treatment options that target axonal degeneration associated disorders. Across various studies, SARM1 inhibitor has demonstrated the potential to treat multiple neurodegenerative disorders; once approved, these therapies are likely to capture a sizeable market share in the coming future. Further, we expect the first product to be commercially launched in 2033; post that, the market is expected to grow at an annualized rate of 102%.
You can also download the SAMPLE REPORT on SARM1 inhibitors by Roots Analysis.